The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...
Hosted on MSN7d
Parkinson's disease could be treated by FDA-approved cancer drug after major research breakthroughA major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
Trastuzumab deruxtecan is approved for HR ... ultralow metastatic breast cancer following endocrine therapy.” Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC) developed ...
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.
AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical ...
The approval emphasizes the importance of HER2 status testing in metastatic breast cancer to identify eligible patients for Enhertu treatment. The antibody drug conjugate was approved for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback